Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Rating of “Buy” from Brokerages

Jasper Therapeutics, Inc. (NASDAQ:JSPRGet Free Report) has earned an average recommendation of “Buy” from the ten brokerages that are presently covering the company, MarketBeat Ratings reports. Ten analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $62.50.

JSPR has been the topic of several analyst reports. UBS Group initiated coverage on Jasper Therapeutics in a report on Thursday, February 13th. They issued a “buy” rating and a $38.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Jasper Therapeutics in a research note on Tuesday, March 11th. Royal Bank of Canada cut their target price on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a research note on Thursday, January 9th. JMP Securities reissued a “market outperform” rating and issued a $70.00 target price on shares of Jasper Therapeutics in a research note on Monday, January 6th. Finally, BMO Capital Markets started coverage on Jasper Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $63.00 target price on the stock.

Read Our Latest Analysis on Jasper Therapeutics

Institutional Trading of Jasper Therapeutics

Several large investors have recently bought and sold shares of JSPR. Braidwell LP bought a new stake in Jasper Therapeutics during the 3rd quarter valued at approximately $9,091,000. Boxer Capital Management LLC bought a new stake in Jasper Therapeutics during the 4th quarter valued at approximately $7,483,000. Integral Health Asset Management LLC boosted its position in Jasper Therapeutics by 85.7% during the 4th quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock valued at $13,897,000 after acquiring an additional 300,000 shares in the last quarter. Ally Bridge Group NY LLC boosted its position in shares of Jasper Therapeutics by 82.7% in the 3rd quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock worth $7,514,000 after purchasing an additional 180,852 shares in the last quarter. Finally, Soleus Capital Management L.P. boosted its position in shares of Jasper Therapeutics by 11.2% in the 4th quarter. Soleus Capital Management L.P. now owns 1,494,420 shares of the company’s stock worth $31,951,000 after purchasing an additional 150,755 shares in the last quarter. 79.85% of the stock is owned by institutional investors.

Jasper Therapeutics Trading Up 2.0 %

JSPR opened at $5.49 on Monday. The company has a market cap of $82.47 million, a P/E ratio of -1.16 and a beta of 2.23. The business’s 50-day moving average price is $6.45 and its 200-day moving average price is $15.78. Jasper Therapeutics has a 12 month low of $4.55 and a 12 month high of $31.01.

Jasper Therapeutics (NASDAQ:JSPRGet Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($1.62) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.35). Equities research analysts forecast that Jasper Therapeutics will post -4.47 earnings per share for the current fiscal year.

About Jasper Therapeutics

(Get Free Report

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.

Further Reading

Analyst Recommendations for Jasper Therapeutics (NASDAQ:JSPR)

Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.